Case Study: a leading neoadjuvant chemotherapy service provider predicts breast cancer treatment response with Quibim's radiomics AI

Developing a radiomics-based tool for predicting pathological complete response (pCR) to neoadjuvant chemotherapy in breast cancer

The customer, a leading neoadjuvant chemotherapy service provider, faced the challenge of predicting which breast cancer patients would respond to neoadjuvant chemotherapy. This difficulty in personalizing treatment plans often led to suboptimal patient outcomes and unnecessary toxicities. They partnered with Quibim to develop a predictive tool to address this need.

Quibim developed a radiomics-based AI tool using MRI and PET imaging to predict pathological complete response. This solution, which segments lesions and extracts features from medical images, will be integrated into their QP-Breast® product. The Quibim tool enhances breast cancer care by providing oncologists with advanced predictive capabilities to make more precise, informed treatment decisions, representing a major advancement in personalized oncology.